Cormorant Asset Management, LP Axsome Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $2.34 Million - $3.61 Million	40,000 Added 13.33%	340,000 $24.4 Million
Q1 2023 May 15, 2023	SELL	$58.39 - $75.0 $1.46 Million - $1.88 Million	-25,000 Reduced 7.69%	300,000 $18.5 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $13 Million - $25.9 Million	325,000 New	325,000 $25.1 Million
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $4.46 Million - $9.58 Million	205,000 New	205,000 $7.85 Million
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $10.1 Million - $14.7 Million	-200,000 Closed	0 $0

Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $3.32 Million - $4.33 Million	-50,000 Reduced 20.0%	200,000 $16.3 Million
Q3 2020 Nov 16, 2020	SELL	$68.34 - $85.84 $6.83 Million - $8.58 Million	-100,000 Reduced 28.57%	250,000 $17.8 Million
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $7.48 Million - $14.8 Million	-150,000 Reduced 30.0%	350,000 $28.8 Million
Q1 2020 May 15, 2020	SELL	$41.2 - $101.31 $4.12 Million - $10.1 Million	-100,000 Reduced 16.67%	500,000 $29.4 Million
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $10 Million - $63.7 Million	600,000 New	600,000 $62 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.44B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.